Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL38 for Intra-Operative Imaging in Ovarian Cancer
NCT04941378Phase 1Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pafolacianine in ovarian cancer, sponsored by Abramson Cancer Center. Primary endpoint: Positive Predictive Value at 4 weeks. Planned start May 2022; status: withdrawn.
02
Drugs
pafolacianine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04941378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941378.